AstraZeneca Plc said it had a key lung cancer drug approved in China, opening up a new market for the therapy and allowing U.K.’s second-biggest drugmaker to reach thousands of new patients in country ...
- Zacks•3 days ago
Shares of London-based pharma giant, AstraZeneca plc (AZN) have risen 13.4% this year so far, while the Zacks classified Large-Cap Pharma industry increased 6.4%.
- Market Realist•4 days ago
On December 9, 2016, the FDA accepted for review its first-ever biologics license application (or BLA) submitted by AstraZeneca (AZN).
AZN.L : Summary for ASTRAZENECA PLC ORD SHS $0.25 - Yahoo Finance
AstraZeneca PLC (AZN.L)
LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
|Bid||4,715.00 x 6100|
|Ask||4,985.00 x 13000|
|Day's Range||4,896.25 - 4,975.12|
|52 Week Range||3,680.00 - 5,505.00|
|PE Ratio (TTM)||17.86|
|Dividend & Yield||2.80 (4.68%)|
|1y Target Est||N/A|